Evidence map›Paper›PMID 40390069›Full record

ArticlePediatric rheumatology online journal2025

Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis.

Athimalaipet V Ramanan, Andrew D Dick, Thomas Jaki, Gianmarco Caruso, David S Robertson, Ashley P Jones, Ben Hardwick, Sian Drake, Balini Balasubramaniam, Coziana Ciurtin and 9 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Characteristics of JIA-associated uveitis at the age of transition.Pediatric rheumatology online journal · 2026
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Athimalaipet V RamananBristol Royal Hospital for Children, Upper Maudlin Street, Bristol, BS2 8BJ, UK. avramanan@hotmail.com.
Andrew D DickBristol Medical School, University of Bristol, Bristol, UK.
Thomas JakiUniversity of Regensburg, Regensburg, Germany.
Gianmarco CarusoUniversity of Cambridge, Cambridge, UK.
David S RobertsonUniversity of Cambridge, Cambridge, UK.
Ashley P JonesLiverpool Clinical Trials Centre, The University of Liverpool, Liverpool, UK.
Ben HardwickLiverpool Clinical Trials Centre, The University of Liverpool, Liverpool, UK.
Sian DrakeLiverpool Clinical Trials Centre, The University of Liverpool, Liverpool, UK.
Balini BalasubramaniamUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Coziana CiurtinCentre for Adolescent Rheumatology, University College London, London, UK.
Ivan FoeldvariHamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany.
Elke O KrepsGhent University Hospital, Ghent, Belgium.
Alice LeahyUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Kristina MayUniversity Hospital Southampton NHS Foundation Trust, Southampton, UK.
Pierre QuartierUniversité Paris Cité, Paris, France.
Matthieu P RobertOPHTARA reference center, Ophthalmology Department, Necker-Enfants malades hospital, APHP, Paris, France.
Gabriele SimoniniRheumatology unit, ERN ReCONNET center, FIRENZE and NEUROFARBA Department, Meyer Children's Hospital IRCCS, University of Florence, Florence, Italy.
Catherine GulyBristol Eye Hospital, Bristol, UK.
Michael W BeresfordDepartment of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.

Funding

Novartis Pharmaceuticals UK Limited CAIN457A2232T
6 · The paper itself

Abstract

backgroundJuvenile idiopathic arthritis (JIA)-associated uveitis and chronic anterior uveitis in children may result in permanent sight loss. Currently, the only licensed and approved treatment for JIA-uveitis is adalimumab. However, even in patients where adalimumab may be initially effective, therapeutic response may subside for example, due to neutralising drug antibodies. Further treatment options are necessary to prevent sight loss in children with uveitis. Interleukin 17 is elevated in uveitis. Inhibition of interleukin 17 ameliorates inflammation in mouse models of uveitis. Secukinumab, an antibody which neutralizes interleukin 17 A, has been shown to be partially effective in adult uveitis. The objective of the Bayesian consensus meeting was to quantify prior expert opinion about the potential utility of secukinumab in treatment of uveitis in JIA.

methodsNine international experts in paediatric rheumatology, paediatric ophthalmology and/or paediatric uveitis took part in a structured Bayesian prior elicitation meeting.

resultsThe final consensus was that adalimumab is expected to yield a higher response rate than secukinumab (mean 0.67 vs. 0.55). The uncertainty in the response rate on secukinumab is somewhat larger than for adalimumab. The equivalent sample size for the prior distribution of adalimumab is 15.7 and 13.1 for secukinumab. The decisions based on the combined evidence would still be driven by the trial data, yet substantial enhancement of the power of the study can be expected by adding information from the equivalent of almost 30 patients.

conclusionsThe Bayesian analysis adds substantial enhancement of the power of the study and supports a head-to-head trial of adalimumab and secukinumab for JIA-associated uveitis and chronic anterior uveitis.

trial registrationISRCTN 12,427,150 Registration date 14/02/2023. EudraCT 2022-003068-26 Registration date 07/09/2022.

Indexed as

AdalimumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, JuvenileUveitisUveitis, AnteriorBayes TheoremChildChronic DiseaseHumansTreatment OutcomeAdalimumabAntibodies, Monoclonal, HumanizedAntirheumatic AgentssecukinumabBayesian priorBiologicsClinical trialJuvenile idiopathic arthritisUveitis

Identifiers

PMID40390069
PMCPMC12090588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.